Cargando…
Efficacy and risks of fondaparinux 7.5 mg for deep vein thrombosis after total knee arthroplasty
OBJECTIVES: High-dose fondaparinux therapy at 7.5 mg/day (FPX 7.5 mg) for deep vein thrombosis (DVT) may increase the risk of hemorrhage. We investigated the efficacy and safety of FPX 7.5 mg to treat DVT after total knee arthroplasty. METHODS: This study included 101 patients (91 with osteoarthriti...
Autores principales: | Nojiri, Sho, Hayakawa, Kazue, Date, Hideki, Yamada, Harumoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fujita Medical Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766234/ https://www.ncbi.nlm.nih.gov/pubmed/35111494 http://dx.doi.org/10.20407/fmj.2017-020 |
Ejemplares similares
-
Snapping knee due to the biceps femoris tendon treated with repositioning of the anomalous tibial insertion
por: Date, Hideki, et al.
Publicado: (2011) -
Preoperative prevalence of deep vein thrombosis in patients scheduled to have surgery for degenerative musculoskeletal disorders
por: Sato, Keigo, et al.
Publicado: (2021) -
Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
por: Shimizu, Kazuhiro, et al.
Publicado: (2016) -
Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients
por: Zhang, Zhi-Hao, et al.
Publicado: (2017) -
The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist
por: Shimizu, Kazuhiro, et al.
Publicado: (2018)